ARKK Holdings of Beam Therapeutics (BEAM) - Updated Daily
Join Premium Plan
Key Statistics
EarningsSee Full Calendar
| Date | May 09, 2022 | Revenue | Expected0 Actual$8.43m | EPS | Expected-$1.32 Actual-$1.01 |
|---|
Statistics
Institutional Ownership Trends
News That Matters
| Description | |
|---|---|
| Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. | |
| Website | |
| beamtx.com |
Research Notes and Commentary for BEAM
January 19, 2021